This Is MS Multiple Sclerosis Community: Knowledge & Support

Multiple sclerosis patients who took the oral investigational agent fingolimod were better able to maintain activities of daily living over a year than those treated with injected interferon beta-1A, according to a study presented here at CMSC-ACTRIMS.

Patients taking the standard injected therapy interferon beta-1A (Avonex) had more pronounced decline in their ability to perform ADLs based on a patient reported activity scale -- dropping by 0.43 points over 12 months, compared with those on either of two doses of fingolimod, whose scores dropped by just 0.08 and 0.12 points (P<0.05 for both comparisons), Jeffrey Cohen, MD, of the Neurologic Institute of the Cleveland Clinic in Cleveland, Ohio, reported.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis